Clinical trial
Rituximab for Prevention of Chronic GVHD
NCT00379587 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00379587 |
|---|---|
| Title | Rituximab for Prevention of Chronic GVHD |
| Official title | A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Genentech, Inc. Industry Biogen |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hematological Malignancies |
| Intervention type | Drug |
| Interventions | Rituximab, 375 mg/m2 RRituximab |
| Enrollment | 65 |
| Start date | Sep 1, 2006 |
| Primary completion | Aug 1, 2012 |
| Completion | Aug 1, 2012 |
| First posted | Sep 22, 2006 |
| Last update posted | Mar 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: